In October, the National Health Surveillance Agency (Anvisa) approved the first systematic treatment for alopecia areata, an autoimmune disease that causes hair loss.
This means that baricitinib, also known by the trade name Olumiant, can be administered to adult patients with severe disease for treatment throughout the body, instead of a specific location.
It is important to note that the condition is different from androgenetic alopecia, the baldness that we inherit from our family members.
As this is a new therapeutic indication, the medicine is now available. In a note, manufacturer Eli Lilly do Brasil informed g1 that the 4 mg dosage has a maximum consumer price (PMC) of R$5,648.25, excluding taxes.
In online pharmacies, however, the retail price of the medicine tends to be more expensive.
According to the FDA, the US health regulatory agency, which also approved Olumiant’s indication for alopecia areata, the efficacy and safety of baricitinib has been studied in several studies. One study even demonstrated at least 80% scalp hair coverage in patients after 36 weeks of treatment (see image above).
Another survey showed that 22% of patients (out of 184) who received 2 milligrams of Olumiant and another 35% (out of 281) who received 4 milligrams achieved adequate scalp coverage. On the other hand, only 5% of patients (out of a total of 189) in this same research who received placebo (inert substances) showed the same result.
In Brazil, Olumiant is also approved for the treatment of Covid-19 in certain hospitalized adults.
In addition, baricitinib is also registered for the treatment of moderate to severe active rheumatoid arthritis and moderate to severe atopic dermatitis. At the beginning of 2022, the drug was also approved as the first medicine for the treatment of Covid-19 in the Unified Health System.
In October, the National Health Surveillance Agency (Anvisa) approved the first systematic treatment for alopecia areata, an autoimmune disease that causes hair loss.
This means that baricitinib, also known by the trade name Olumiant, can be administered to adult patients with severe disease for treatment throughout the body, instead of a specific location.
It is important to note that the condition is different from androgenetic alopecia, the baldness that we inherit from our family members.
As this is a new therapeutic indication, the medicine is now available. In a note, manufacturer Eli Lilly do Brasil informed g1 that the 4 mg dosage has a maximum consumer price (PMC) of R$5,648.25, excluding taxes.
In online pharmacies, however, the retail price of the medicine tends to be more expensive.
According to the FDA, the US health regulatory agency, which also approved Olumiant’s indication for alopecia areata, the efficacy and safety of baricitinib has been studied in several studies. One study even demonstrated at least 80% scalp hair coverage in patients after 36 weeks of treatment (see image above).
Another survey showed that 22% of patients (out of 184) who received 2 milligrams of Olumiant and another 35% (out of 281) who received 4 milligrams achieved adequate scalp coverage. On the other hand, only 5% of patients (out of a total of 189) in this same research who received placebo (inert substances) showed the same result.
In Brazil, Olumiant is also approved for the treatment of Covid-19 in certain hospitalized adults.
In addition, baricitinib is also registered for the treatment of moderate to severe active rheumatoid arthritis and moderate to severe atopic dermatitis. At the beginning of 2022, the drug was also approved as the first medicine for the treatment of Covid-19 in the Unified Health System.
